On the basis of preliminary bacteriological and toxicological findings, an open study was devised for the treatment of patients with severe infections using the new antibiotic cefuroxime.
Materials and Alethods
Twenty in-patients were included in the study. Their age and sex distribution ( Table 1) is that of an ageing population. One patient had previously developed a rash on ampicillin. All patients were severely ill and suffered from various diseases (Table 2 ). Laboratory investigations indicated an impaired renal function in 15 patients with increased serum creatinine or blood urea. The infections treated were lower respiratory tract infection (graded acute and severe, 4 patients), urinary tract infection (moderate, chronic or recurrent, 15 patients) and skin and soft tissue infection (acute, but of moderate severity, 1 patient, Table 3 ).
Twelve patients had received antibiotic prior to cefuroxime. Previous treatments included ampicillin per os and i.v., doxycycline per os, gentamicin i.m., tetracycline per os and cotrimoxazole per os (Table 4 ). Most of these patients had either failed on their previous treatment or had infecting organisms resistant to the antibiotic being used.
All patients were given 750 mg of cefuroxime 3 times daily as an i.m. dose in the buttock or i.v. The duration of treatment was 11.3±2.9 days, and patients received bed rest. Insulin, steroids and in one case chlorthalidone were continued because of concurrent disease. Criteria used for clinical assessment were: Successcomplete remission of signs and symptoms. Improvementsymptoms still present, but improving. Failureno improvement or worsening.
Criteria used for bacteriological assessment were: Successelimination of causative organism. Failurepersistence of causative organism. Unassessableno causative organism isolated or no follow-up bacteriology reported.
Results
Clinical response to cefuroxime treatment is shown in Table 5 . In most cases, relief was reported in 2-4 days. Even some patients with resistant organisms reported relief of symptoms. The only failure was a case of recurrent pyelonephritis in a patient previously treated with unknown antibiotics. The isolated organism, an Enterococcus was eradicated, but fever persisted and the patient was subsequently given kanamycin and sulphatrimethoprim.
Six of the 12 patients who had previously received other antibiotics were successfully treated with cefuroxime, while 3 more improved and 2 were unassessable.
Bacteriological response is given in Table 6 . All organisms that were sensitive or moderately sensitive to cefuroxime were eradicated. Resistant Pseudomonas persisted in one case. No repeated bacteriology was carried out in one patient with resistant Klebsiella pneumonice. One failure was observed in a case of pyelitis due to Klebsiella pneumonie, initially thought to be moderately sensitive. At the end of treatment the Klebsiella was still present, producing an inhibition zone not very different from the pretreatment situation. Thus the organism may have been initially resistant.
Among the 12 patients who had received unsuccessful antibiotic therapy prior to cefuroxime, the causative organisms were eradicated after cefuroxime treatment in 8 instances. One 3.9 110 patient had a resistant Pseudomonas; 2 were unassessable; the remaining patient with a moderately sensitive Klebsiella pneumonia had been a treatment failure on doxyxycline and was also a bacteriological failure on cefuroxime. He later showed improvement when treated with gentamicin (3 x 80 mg i.m.).
Ten cases of urinary tract infection received no other antimicrobial therapy after treatment with cefuroxime. Six of them underwent follow-up urine cultures, 2-4 weeks after completion of treatment. No pathogens were found.
Of the observed side effects, 10 patients complained of pain at the site of injection, 2 of them reporting the pain as severe. No adverse reaction was noted in a patient with a previous history of ampicillin rash.
A reduction in hmmoglobin content was observed in 7 cases ( Table 7) . Because of the severe condition of these patients, it cannot be considered with certainty as a drug related con-dition. Enzymatic changes are shown in Table 8 . In some cases, an increase in serum alkaline phosphatase activity was recorded, as well as an increase in serum glutamic-oxaloacetic transaminase activity and serum bilirubin content.
Renal effects are also shown in Table 8 . In 15 of the 20 patients, no changes were recorded and in 3 of the other 5, the changes seen were attributed to the disease process. In 13 cases, blood urea was increased before cefuroxime treatment. In 12 it decreased during cefuroxime treatment, returning to normal in 3 of them. Eleven patients were followed up after treatment. Their blood urea levels remained lower than they had been prior to treatment.
These preliminary results on such a small number of patients can only indicate the need for further study of the new drug, but its safety and effectiveness may make it a useful addition to the present range of antibiotics.
